The injectable authorized generic reportedly facilitates gallbladder imaging as well as X-ray imaging of the intestinal tract.
Sincalide (Fresenius Kabi), an injectable authorized generic to Bracco Diagnostics’ Kinevac®, is now available in the United States for multiple indications in adults to aid in the diagnosis of gallbladder, intestinal and pancreatic issues.
The agent is indicated for the stimulation of gallbladder contraction, which can be assessed via multiple imaging modalities, or to obtain a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. Clinicians may also utilize Sincalide to facilitate faster transit of a barium meal through the small bowel, which may help reduce radiation time and dosing for fluoroscopy and X-ray imaging of the intestines.
Another indication for Sincalide is stimulation of pancreatic secretion before obtaining duodenal aspirate for enzyme assessment.
“Diagnostic pharmaceutical agents like Sincalide play a critical role in patient diagnosis, and Fresenius Kabi’s addition of Sincalide provides health care facilities nationwide with new options to ensure timely patient care,” noted John Ducker, the president and CEO of Fresenius Kabi.
Contraindications for Sincalide are intestinal obstruction and history of hypersensitivity to sincalide, including anaphylaxis and anaphylactic shock.
In addition, official prescribing information warns that Sincalide may be associated with adverse reactions including nausea, vomiting, abdominal pain or cramping, dizziness, and flushing. Patients who are pregnant should be advised that Sincalide can affect smooth muscle, which may increase the risk of spontaneous abortion or premature labor.
(Editor’s note: For related content, see “Current Considerations with MRI Contrast Agents for Patients with Liver Metastasis and Kidney Impairment” and “Could Photon Counting CT Supplant MRI for Imaging Assessment of Hepatic Steatosis?”)